Limits...
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

Valeyre D, Albera C, Bradford WZ, Costabel U, King TE, Leff JA, Noble PW, Sahn SA, du Bois RM - Respirology (2014)

Bottom Line: Gastrointestinal and skin-related events were the most commonly reported adverse events; these were almost always mild to moderate in severity, and rarely led to treatment discontinuation.Elevations (>3× upper limit of normal) in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) occurred in 21/789 (2.7%) patients; the adjusted incidence of AST/ALT elevations was 1.7 per 100 PEY.This comprehensive analysis of safety in a large cohort of IPF patients receiving pirfenidone for a total of 2059 PEY demonstrates that long-term treatment with pirfenidone is safe and generally well tolerated.

View Article: PubMed Central - PubMed

Affiliation: Hospital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France.

Show MeSH

Related in: MedlinePlus

Study profile. *Patients who enrolled after Protocol Amendment 2 (15 September 2005) were treated with a target maintenance dose of 2403 mg/day, adminstered with food three times daily following a 2-week dose escalation period.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230393&req=5

fig01: Study profile. *Patients who enrolled after Protocol Amendment 2 (15 September 2005) were treated with a target maintenance dose of 2403 mg/day, adminstered with food three times daily following a 2-week dose escalation period.

Mentions: All patients who were randomized to treatment with pirfenidone and received at least one dose of study drug in the Phase 3 CAPACITY studies and all patients who received at least one dose of pirfenidone in one of two ongoing open-label studies were included in the analysis (Fig. 1). The CAPACITY studies (Study 004 and Study 006) were randomized, double-blind, placebo-controlled studies evaluating pirfenidone in patients with IPF. The open-label studies included Study 002, a compassionate-use study in patients with either IPF or secondary pulmonary fibrosis, and Study 012 (RECAP), an open-label extension study in patients who completed either of the two CAPACITY studies or the ongoing ASCEND study (patients who completed the ASCEND study enrolled in Study 012 after the interim data cut-off date and were therefore not included in the analysis).


Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

Valeyre D, Albera C, Bradford WZ, Costabel U, King TE, Leff JA, Noble PW, Sahn SA, du Bois RM - Respirology (2014)

Study profile. *Patients who enrolled after Protocol Amendment 2 (15 September 2005) were treated with a target maintenance dose of 2403 mg/day, adminstered with food three times daily following a 2-week dose escalation period.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230393&req=5

fig01: Study profile. *Patients who enrolled after Protocol Amendment 2 (15 September 2005) were treated with a target maintenance dose of 2403 mg/day, adminstered with food three times daily following a 2-week dose escalation period.
Mentions: All patients who were randomized to treatment with pirfenidone and received at least one dose of study drug in the Phase 3 CAPACITY studies and all patients who received at least one dose of pirfenidone in one of two ongoing open-label studies were included in the analysis (Fig. 1). The CAPACITY studies (Study 004 and Study 006) were randomized, double-blind, placebo-controlled studies evaluating pirfenidone in patients with IPF. The open-label studies included Study 002, a compassionate-use study in patients with either IPF or secondary pulmonary fibrosis, and Study 012 (RECAP), an open-label extension study in patients who completed either of the two CAPACITY studies or the ongoing ASCEND study (patients who completed the ASCEND study enrolled in Study 012 after the interim data cut-off date and were therefore not included in the analysis).

Bottom Line: Gastrointestinal and skin-related events were the most commonly reported adverse events; these were almost always mild to moderate in severity, and rarely led to treatment discontinuation.Elevations (>3× upper limit of normal) in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) occurred in 21/789 (2.7%) patients; the adjusted incidence of AST/ALT elevations was 1.7 per 100 PEY.This comprehensive analysis of safety in a large cohort of IPF patients receiving pirfenidone for a total of 2059 PEY demonstrates that long-term treatment with pirfenidone is safe and generally well tolerated.

View Article: PubMed Central - PubMed

Affiliation: Hospital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France.

Show MeSH
Related in: MedlinePlus